Deramiocel for Duchenne Muscular Dystrophy: FDA Review Raises Questions About Cardiac Benefit
FDA advisers reviewed deramiocel’s cardiac evidence in Duchenne muscular dystrophy, weighing potential preservation of heart function against uncertain clinical benefit, safety, and long-term outcomes.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.